PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Form 8-K
February 03, 2015
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
TORW 0-K
CURRENT REPORT
CURRENT REPORT
CURRENT REPORT  Pursuant to Section 13 or 15(d) of
Pursuant to Section 13 or 15(d) of
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of  The Securities Exchange Act of 1934  Date of Report (Date of earliest event reported)
Pursuant to Section 13 or 15(d) of  The Securities Exchange Act of 1934  Date of Report (Date of earliest event reported)
Pursuant to Section 13 or 15(d) of  The Securities Exchange Act of 1934  Date of Report (Date of earliest event reported)
Pursuant to Section 13 or 15(d) of  The Securities Exchange Act of 1934  Date of Report (Date of earliest event reported)
Pursuant to Section 13 or 15(d) of  The Securities Exchange Act of 1934  Date of Report (Date of earliest event reported)  February 3, 2015  Pacific Biosciences of California, Inc.
Pursuant to Section 13 or 15(d) of  The Securities Exchange Act of 1934  Date of Report (Date of earliest event reported)  February 3, 2015

Delaware 001-34899 16-1590339

(State or other jurisdiction (Commission (IRS

Employer

of incorporation) File Number)

Identification

No.)

1380 Willow Road

Menlo Park, California 94025

(Address of principal executive offices, including zip code)

(650) 521-8000

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02.Results of Operations and Financial Condition.

On February 3, 2015, Pacific Biosciences of California, Inc. reported its financial results for its fourth fiscal quarter ended December 31, 2014. A copy of the press release containing the announcement is included as Exhibit 99.1 and is incorporated herein by reference.

This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, "Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

99.1 Press Release dated February 3, 2015 titled "Pacific Biosciences Reports Fourth Quarter 2014 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02).

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pacific Biosciences of California, Inc.

By: /s/ Brian B. Dow Brian B. Dow

Vice President and Principal Accounting Officer

Date: February 3, 2015

## **EXHIBIT INDEX**

Exhibit No. Description

99.1 Press Release dated February 3, 2015 titled "Pacific Biosciences Reports Fourth Quarter 2014 Financial

Results" (furnished and not filed herewith solely pursuant to Item 2.02).